173 related articles for article (PubMed ID: 37393342)
1. Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia.
Liu J; Min S; Kim D; Park J; Park E; Pei S; Koh Y; Shin DY; Byun JM; Ko M; Yoon SS; Hong J
Leukemia; 2023 Aug; 37(8):1638-1648. PubMed ID: 37393342
[TBL] [Abstract][Full Text] [Related]
2. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
3. Decreased vitamin C uptake mediated by SLC2A3 promotes leukaemia progression and impedes TET2 restoration.
Liu J; Hong J; Han H; Park J; Kim D; Park H; Ko M; Koh Y; Shin DY; Yoon SS
Br J Cancer; 2020 May; 122(10):1445-1452. PubMed ID: 32203209
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of GLUT3 Promotes Apoptosis and Chemosensitivity of Acute Myeloid Leukemia Cells via EGFR Signaling.
Zhuang Y; Zhao J; Xu X; Bi L
Arch Iran Med; 2018 Feb; 21(2):73-78. PubMed ID: 29664658
[TBL] [Abstract][Full Text] [Related]
5. Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.
Pethusamy K; Seethy A; Dhar R; Karmakar A; Chaudhary S; Bakhshi S; Palanichamy JK; Chopra A; Chauhan SS; Karmakar S
Leuk Lymphoma; 2022 Dec; 63(14):3426-3432. PubMed ID: 36165590
[TBL] [Abstract][Full Text] [Related]
6. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia.
Zhao H; Zhu H; Huang J; Zhu Y; Hong M; Zhu H; Zhang J; Li S; Yang L; Lian Y; Wang S; Mao J; Chen Y; Li J; Qian S
Leuk Res; 2018 Mar; 66():1-7. PubMed ID: 29331774
[TBL] [Abstract][Full Text] [Related]
7. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal.
Li Y; Xue M; Deng X; Dong L; Nguyen LXT; Ren L; Han L; Li C; Xue J; Zhao Z; Li W; Qing Y; Shen C; Tan B; Chen Z; Leung K; Wang K; Swaminathan S; Li L; Wunderlich M; Mulloy JC; Li X; Chen H; Zhang B; Horne D; Rosen ST; Marcucci G; Xu M; Li Z; Wei M; Tian J; Shen B; Su R; Chen J
Cell Stem Cell; 2023 Aug; 30(8):1072-1090.e10. PubMed ID: 37541212
[TBL] [Abstract][Full Text] [Related]
8. Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2.
Zhao H; Lu J; Yan T; Han F; Sun J; Yin X; Chen L; Shen C; Wunderlich M; Yun W; Yang L; Chen L; Su D; Bohlander SK; Wang F; Mulloy JC; Li C; Chen J; Huang H; Jiang X
Cell Rep; 2022 Jan; 38(4):110253. PubMed ID: 35081358
[TBL] [Abstract][Full Text] [Related]
9. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.
Aivalioti MM; Bartholdy BA; Pradhan K; Bhagat TD; Zintiridou A; Jeong JJ; Thiruthuvanathan VJ; Pujato M; Paranjpe A; Zhang C; Levine RL; Viny AD; Wickrema A; Verma A; Will B
Blood Cancer Discov; 2022 Sep; 3(5):444-467. PubMed ID: 35820129
[TBL] [Abstract][Full Text] [Related]
10. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
Lyu Y; Lou J; Yang Y; Feng J; Hao Y; Huang S; Yin L; Xu J; Huang D; Ma B; Zou D; Wang Y; Zhang Y; Zhang B; Chen P; Yu K; Lam EW; Wang X; Liu Q; Yan J; Jin B
Leukemia; 2017 Dec; 31(12):2543-2551. PubMed ID: 28400619
[TBL] [Abstract][Full Text] [Related]
11. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
12. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
[TBL] [Abstract][Full Text] [Related]
13. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognosis analysis of
Zhang T; Zhao Y; Zhao Y; Zhou J
Aging (Albany NY); 2020 Mar; 12(6):5031-5047. PubMed ID: 32209730
[No Abstract] [Full Text] [Related]
15. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
[TBL] [Abstract][Full Text] [Related]
16. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.
De Luca L; Trino S; Laurenzana I; Tagliaferri D; Falco G; Grieco V; Bianchino G; Nozza F; Campia V; D'Alessio F; La Rocca F; Caivano A; Villani O; Cilloni D; Musto P; Del Vecchio L
Cell Death Dis; 2017 Jun; 8(6):e2849. PubMed ID: 28569789
[TBL] [Abstract][Full Text] [Related]
18. Compound C induces autophagy and apoptosis in parental and hydroquinone-selected malignant leukemia cells through the ROS/p38 MAPK/AMPK/TET2/FOXP3 axis.
Chiou JT; Huang CH; Lee YC; Wang LJ; Shi YJ; Chen YJ; Chang LS
Cell Biol Toxicol; 2020 Aug; 36(4):315-331. PubMed ID: 31900833
[TBL] [Abstract][Full Text] [Related]
19. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia.
Bensberg M; Rundquist O; Selimović A; Lagerwall C; Benson M; Gustafsson M; Vogt H; Lentini A; Nestor CE
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34413196
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
